stock
RNA · Atrium Therapeutics, Inc.
What Atrium Therapeutics, Inc. reports to the SEC, read from its filings.
Open in the appPrice
The live RNA price and today's change.
Sign in to see thisChart
Thirty days of daily bars, with signal levels drawn on them.
Sign in to see thisSignals
The latest signal group Nakagai's scanner recorded on RNA.
Sign in to see thisOptions positioning
Gamma exposure levels from the options market.
Sign in to see thisTechnicals
Trend, momentum and volatility gauges per timeframe.
Sign in to see thisWhat it is
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Filer (SEC EDGAR)
- EDGAR filing index
- Shares outstanding
- 17,105,643 as of 2026-08-03 (XBRL frame CY2026Q2I)
Key stats
Valuation
- P/E
- Locked
- P/S
- Locked
- P/B
- Locked
- Enterprise value
- Locked
- EV/EBIT
- Locked
- FCF yield
- Locked
Margins
- Gross
- —
- Operating
- —
- Net
- —
Returns
- ROE
- —
- ROA
- —
Health
- Current ratio
- 8.7x
- Debt/equity
- —
Deep value
- NCAV
- $209.12M
- NCAV per share
- $12.22
- Price/NCAV
- Locked
- NNWC
- $6.40M
- NNWC per share
- $0.37
- Price/NNWC
- Locked
Valuation and the price multiples are built on the live price. Trailing twelve months to —; balance sheet at 2026-06-30.
Sign in to see thisDebt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue | Gross profit (not reported by this company) | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | $3.00M | —Gross profit: unreported by this company. | -$22.62M | -$20.19M | 10-Q filed 2026-08-13 |
| 2026-03-31 | $19.64M | —Gross profit: unreported by this company. | -$17.28M | -$16.63M | 10-Q filed 2026-08-13 Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-06-30 | $3.85M | —Gross profit: unreported by this company. | -$12.86M | -$12.88M | 10-Q filed 2026-08-13 |
| 2025-03-31 | $1.57M | —Gross profit: unreported by this company. | -$7.45M | -$7.45M | 10-Q filed 2026-08-13 Assembled from more than one filing; the filing above is only the newest of them. |
- Assets
- $280.51M
- Equity
- $214.58M
Balance as of 2026-06-30.
Ten years
No annual results reported by SEC for this filer.
Company filings
events
5% owners ()
RA Capital Management, L.P.
Stake update
Sessa Capital IM, L.P.
Passive stake
T. Rowe Price Associates, Inc.
Stake update
BlackRock, Inc.
Stake update
RA Capital Management, L.P.
Passive stake
Insiders, politicians and funds
Insider trades, last 90 days
No insider buys or sales filed in the last 90 days.
Politician trades, last 90 days
No politician trades filed in the last 90 days.
Funds
None of the tracked funds held this at their last 13F.
News
Stories that named RNA, and the market events around them.
Sign in to see thisBoard
The RNA board could not be loaded.
Retry the RNA boardnakagai
Signals on RNA come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Members post on the RNA board